文献速递泌尿系感染前列腺增生与排尿功能障碍

门诊膀胱尿道镜零抗菌药物预防方案的安全性与有效性

Safety and effectiveness of zero antimicrobial prophylaxis protocol for outpatient cystourethroscopy.
PubMed 文献 · BJU Int · 2019-01-20

在学术中心实施门诊膀胱镜零抗菌药物预防方案前后各一年,共纳入941例患者(72%为男性),比较操作相关抗菌药物预防使用率与膀胱镜后30天内尿路感染(UTI)发生率。方案实施后操作相关抗菌药物预防使用率由30%降至15%(P<0.001),UTI发生率略升高(2.9-3.7%)但无统计学差异(P=0.45),提示减少膀胱尿道镜抗菌药物预防是安全的。

要点

  • 零抗菌药物预防方案使操作相关抗菌药物预防使用率由30%降至15%(P<0.001)。
  • 膀胱镜后UTI发生率略升高但无统计学差异(P=0.45),抗菌药物预防未降低感染率。
  • 导管使用是膀胱镜后UTI唯一显著的患者层面预测因素(OR 1.48,95%CI 1.06-2.06)。

核心结论

  • 实施零抗菌药物预防方案显著减少了操作相关抗菌药物预防使用,UTI发生率无显著变化,抗菌药物预防未降低感染率,支持在门诊减少膀胱尿道镜抗菌药物预防。

研究设计与样本

  • 学术中心实施门诊膀胱镜零抗菌药物预防方案前后各一年病历回顾性分析,共纳入941例患者(72%为男性),方案前513例、方案后427例。

主要发现

  • 方案实施后接受操作相关抗菌药物预防的患者显著减少(30% vs 15%;P<0.001)。
  • 膀胱镜后UTI发生率在方案后组略高(2.9-3.7%),但差异无统计学意义(卡方=0.56,P=0.45)。
  • 研究期间31例UTI中5例(16%)出现发热、4例(13%)出现尿源性脓毒症,两类并发症概率在方案前后组间无显著差异。
  • 膀胱镜后UTI唯一显著的患者层面预测因素为导管使用(OR 1.48,95%CI 1.06-2.06)。
  • UTI发生率在是否接受操作相关抗菌药物预防或膀胱镜时其他抗菌药物使用之间无显著差异。

关键数值与推荐

  • UTI采用美国国家手术质量改进计划(NSQIP)定义。
  • 统计方法包括卡方检验、Fisher精确检验和多因素logistic回归,显著性定义为α<0.05。
  • 比较变量包括年龄、性别、吸烟史、良性前列腺增生(BPH)诊断、糖尿病、免疫抑制、导管使用(留置、耻骨上或间歇)及既往下尿路重建( augmentation cystoplasty 或 neobladder)。

临床怎么用

  • 门诊膀胱尿道镜可考虑不常规使用抗菌药物预防,以促进抗菌药物管理。
  • 对使用导管的患者应关注膀胱镜后UTI风险。
  • 美国泌尿外科学会(AUA)最佳实践声明中的其他患者变量在本研究中未显示预测作用。

局限性

  • 为单中心回顾性研究,样本量941例,可能存在未测量混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To examine compliance and clinical outcomes after implementation of a zero antimicrobial prophylaxis protocol for outpatient cystoscopy in an academic centre. PATIENTS AND METHODS: Medical records of all patients who underwent diagnostic cystoscopy in the year preceding and year following protocol implementation were evaluated for urinary tract infection (UTI) diagnosis within 30 days of cystoscopy. Variables compared between groups included age, sex, smoking history, benign prostatic hyperplasia (BPH) diagnosis, diabetes mellitus, immunosuppression, catheter use (indwelling, suprapubic, or intermittent), and previous lower urinary tract reconstruction (augmentation cystoplasty or neobladder). UTI was defined using the National Surgical Quality Improvement Program definition. Rates were compared between groups, and statistical analyses were performed using chi-squared and Fisher's exact tests and multivariable logistic regression, with significance defined as α < 0.05. RESULTS: In total, 941 patients were included in the analysis (72% men), 513 before protocol initiation, and 427 after. Groups were similar with regard to demographic variables and potential risk factors for infection. After protocol implementation, there was a significant reduction in patients receiving procedural antimicrobial prophylaxis (30% vs 15%; P < 0.001). The incidence of UTI after cystoscopy was slightly higher in the post-protocol group (2.9-3.7%), but the difference was not statistically significant (chi-squared = 0.56, P = 0.45). The incidence of UTI did not significantly differ with procedural antibiotic prophylaxis or with other antibiotic use at time of cystoscopy. Five out of a total of 31 UTIs (16%) over the study period resulted in fever, and four (13%) resulted in urosepsis. The probability of neither complication differed significantly between pre- and post-protocol groups. The only significant patient-level predictor of post-cystoscopy UTI was catheter use (odds ratio 1.48, 95% confidence interval 1.06-2.06). CONCLUSION: Protocol implementation led to a significant decrease in procedural antimicrobial prophylaxis, indicating protocols may be effective tools in promoting antibiotic stewardship. UTI incidence did not change significantly under the protocol, and antibiotic prophylaxis did not decrease infection rate. Our results support catheter use as a risk factor for post-cystoscopy infection, but other patient variables, including those present in the American Urological Association Best Practice statement, were not predictive. In total, this analysis suggests that decreasing antibiotic prophylaxis for cystourethroscopy is safe and can be effective in the outpatient setting.

来源:BJU Int,查看原文。版权归原作者所有。

引用

  1. Clennon EK, Martinez Acevedo A, Sajadi KP, et al. Safety and effectiveness of zero antimicrobial prophylaxis protocol for outpatient cystourethroscopy. BJU Int. 2019. PMID: 30578737. doi:10.1111/bju.14662

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。